IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.

Otros idiomas Immuno-Biological Laboratories Co., Ltd.

Acciones

4570

JP3921300004

Mercado cerrado - Japan Exchange Otros sitios de cotización 08:00:00 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
503 ^JPY	+1,21 %		+6,34 %	+2,03 %

2023

Immuno-Biological Laboratories Co. Ltd. presenta los resultados del ejercicio finalizado el 31 de marzo de 2023

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Immuno-Biological Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23
An unknown buyer agreed to acquire unknown minority stake in CURED Co., Ltd. from Immuno-Biological Laboratories Co., Ltd.	06/02/23
An undisclosed buyer acquired 26.32% stake in Cell Remover Co., Ltd. from Immuno-Biological Laboratories Co., Ltd..	20/12/19
CURED Co., Ltd. announced that it has received ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd.	29/03/19
CURED Co., Ltd. announced that it expects to receive ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd.	27/02/19
Neo Silk Cosmetics Co., Ltd. announced that it has received ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd.	15/11/18
Neo Silk Cosmetics Co., Ltd announced that it expects to receive ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd.	05/11/18
Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd	28/06/17
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥1.4 billion in funding from Whiz Partners Inc.	20/12/16
Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥1.39 billion in funding from Whiz Partners Inc.	01/12/16
CURED Co., Ltd. announced that it has received ¥159.6 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	11/05/16
CURED announced that it expects to receive ¥159.6 million in funding from Trans Genic Inc. and Immuno-Biological Laboratories Co., Ltd.	20/04/16
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it has received ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	31/03/16
Hideki Egawa cancelled the acquisition of 79.6 % stake in M Cosmetics Co., Ltd. from Immuno-Biological Laboratories Co., Ltd., Mitsuru Onishi and others.	27/03/16
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it expects to receive ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	24/03/16
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥406.31 million in funding from Trans Genic Inc., Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	01/03/16
Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥406.31 million in funding from Trans Genic Inc., Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	12/02/16
Hideki Egawa signed a contract to acquire 79.6 % stake in M Cosmetics Co., Ltd. from Immuno-Biological Laboratories Co., Ltd., Mitsuru Onishi and others for ¥20.6 million.	27/03/15
Xseed High Growth I managed by Japan Asia Investment Co. Ltd. acquired Skylight Biotech Inc.	31/12/14
Astellas Pharma and Immuno-Biological Conclude Collaborative Research Agreement	31/12/13

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Immuno-Biological Laboratories Co., Ltd.

Acciones

4570

JP3921300004

Otros idiomas

Filtros